Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CLSA Premium Ltd. ( (HK:6877) ) has issued an announcement.
CLSA Premium Limited has announced its audited results for the year ending December 31, 2024, revealing a significant decrease in sales from its healthcare business, dropping from HK$191,170,000 in 2023 to HK$86,489,000 in 2024. Despite this decline, the company managed to maintain a profit from continuing operations at HK$11,338,000, slightly down from the previous year’s HK$12,830,000, indicating resilience amidst challenging market conditions. The company also proposed a change of its name and amendments to its Memorandum and Articles of Association, signaling potential strategic shifts to better align with its evolving business focus.
More about CLSA Premium Ltd.
CLSA Premium Limited, incorporated in the Cayman Islands, operates within the healthcare industry, focusing on the sale of healthcare products. The company is listed on the Hong Kong Stock Exchange under the stock code 6877.
YTD Price Performance: 51.02%
Average Trading Volume: 2,777,558
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$300.9M
See more insights into 6877 stock on TipRanks’ Stock Analysis page.